HYBIO(SZ:300199) Mei Ri Jing Ji Xin Wen·2025-09-26 03:08Core Viewpoint - Hanyu Pharmaceutical plans to raise up to 968 million yuan through a private placement of A-shares to fund the expansion of its peptide drug production line, R&D upgrades, and to supplement working capital [1][2]. Fund Allocation - Over 50% of the raised funds will be allocated to the expansion of the peptide drug production line and green intelligent upgrades, with 495 million yuan earmarked for this project, which has a total investment of 549 million yuan [2]. - The peptide fragment expansion project will receive 40 million yuan, with a total investment of 45.8 million yuan [2]. - The R&D laboratory upgrade project is set to receive 55 million yuan, with a total investment of 57.75 million yuan [2]. - The semaglutide R&D project will receive 98 million yuan, accounting for 10.12% of the total fundraising, focusing on both domestic injectable and U.S. oral formulations for diabetes treatment [2]. - 280 million yuan will be allocated to supplement working capital [2]. Financial Performance - In the first half of 2025, Hanyu Pharmaceutical reported revenue of 549 million yuan, a year-on-year increase of 114.86%, and a net profit attributable to shareholders of 145 million yuan, up 1504.30% [3]. Market Potential - The global pharmaceutical market is projected to reach 1.646 trillion USD in 2024 and grow to 2.350 trillion USD by 2030, with a CAGR of approximately 6.1% from 2025 to 2030 [4]. - The Chinese pharmaceutical market is expected to grow from 306.5 billion USD in 2024 to 573 billion USD by 2033, with a CAGR of about 7.2% [4]. - The GLP-1 receptor agonist market, including semaglutide, is anticipated to grow from 53.46 billion USD in 2024 to 156.71 billion USD by 2030, with a CAGR of 17.5% [4]. Project Implementation Capability - Hanyu Pharmaceutical has already obtained DMF registration for two liraglutide raw materials in the U.S. and is working on DMF registration for semaglutide [5]. - The company has received approval for clinical trials of semaglutide injection for type II diabetes and weight management [5]. - The fundraising will accelerate the R&D process for semaglutide and enhance the company's production capabilities for peptide raw materials and fragments, creating new profit growth points [5]. Issuance Details - The issuance plan allows for up to 35 qualified investors, including securities investment fund management companies and securities firms, with the issuance price set at no less than 80% of the average trading price over the previous 20 trading days [6].